Related Experiment Video

Updated: Oct 6, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.2K

Uncommon EGFR mutations conducted with osimertinib in patients with NSCLC: a study protocol of phase 2 study

Yusuke Okuma1, Mototsugu Shimokawa2, Kana Hashimoto3

  • 1Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan.

Future Oncology (London, England)
|January 17, 2022
PubMed

Insights

Osimertinib shows promise for previously untreated non-small-cell lung cancer (NSCLC) with uncommon EGFR mutations. This study evaluates its efficacy and safety in this patient population.

Area of Science:

  • Oncology
  • Medical Research
  • Clinical Trials

Background:

  • Uncommon EGFR mutations in NSCLC show limited response to first-generation EGFR-TKIs.
  • Afatinib is FDA-approved for uncommon EGFR-mutated NSCLC, but evidence for osimertinib is limited.

Purpose of the Study:

  • To evaluate the efficacy of osimertinib in previously untreated NSCLC patients with uncommon EGFR mutations.
  • To assess overall response rate, disease control, progression-free survival, and safety.

Main Methods:

  • Single-arm, multicenter, phase 2 clinical trial.
  • Patients received osimertinib as a first-line treatment.
  • Primary endpoint: overall response to osimertinib.

Main Results:

  • Results pending further analysis.
  • Study aims to provide crucial data on osimertinib's effectiveness in this specific NSCLC subgroup.

Conclusions:

  • Osimertinib may offer a new treatment option for NSCLC patients with uncommon EGFR mutations.
  • Further research is needed to confirm these findings and establish optimal treatment strategies.
Keywords:
EGFRcompound mutationsnon-small-cell lung cancerosimertinibphase 2 studytyrosine kinase inhibitoruncommon EGFR mutations

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.1K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.3K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K